{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:42:57Z","timestamp":1774683777937,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research (NIHR)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"The Royal Marsden NHS Foundation Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Institute of Cancer Research"},{"name":"Health Research Board\/Health Service Executive","award":["HRB\/HSE NSAFP\/2014\/1"],"award-info":[{"award-number":["HRB\/HSE NSAFP\/2014\/1"]}]},{"name":"National Medical Research Council Research Fellowship","award":["NMRC\/Fellowship15may003"],"award-info":[{"award-number":["NMRC\/Fellowship15may003"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ejca.2018.02.028","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T04:30:39Z","timestamp":1522470639000},"page":"20-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials"],"prefix":"10.1016","volume":"95","author":[{"given":"Terri Patricia","family":"McVeigh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Diamantis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-3123","authenticated-orcid":false,"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanita S.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winette T.A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela J.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.02.028_bib1","series-title":"ABPI Guidelines for phase 1 clinical trials","author":"Schmidt","year":"2012"},{"issue":"6","key":"10.1016\/j.ejca.2018.02.028_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.02.028_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2018.02.028_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2017.08.010","article-title":"Systemic treatment of renal cell cancer: a comprehensive review","volume":"60","author":"S\u00e1nchez-Gastaldo","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2018.02.028_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.06.005","article-title":"Evolution of anti-HER2 therapies for cancer treatment","volume":"59","author":"Parakh","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"6349","key":"10.1016\/j.ejca.2018.02.028_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejca.2018.02.028_bib7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2018.02.028_bib8","series-title":"DNA Sequencing costs. Data from the NHGRI Genome Sequencing Program (GSP)","author":"KA. W","year":"2017"},{"issue":"32","key":"10.1016\/j.ejca.2018.02.028_bib9","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1200\/JCO.2010.30.5417","article-title":"Quality cancer care for adolescents and young adults: a position statement","volume":"28","author":"Zebrack","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2018.02.028_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ctrv.2006.11.005","article-title":"Participation of adolescents with cancer in clinical trials","volume":"33","author":"Ferrari","year":"2007","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.ejca.2018.02.028_bib11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3109\/0284186X.2012.705891","article-title":"Cancer in adolescents and young adults (15-29 years): a population-based study in The Netherlands 1989-2009","volume":"51","author":"Aben","year":"2012","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2018.02.028_bib12","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(17)30677-0","article-title":"Cancer incidence and mortality among young adults aged 20\u201339 years worldwide in 2012: a population-based study","volume":"18","author":"Fidler","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.02.028_bib13","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/S1470-2045(18)30029-9","article-title":"Young adults: a unique group in cancer epidemiological research","volume":"19","author":"Husson","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.02.028_bib14","doi-asserted-by":"crossref","first-page":"E476","DOI":"10.1210\/jc.2011-1982","article-title":"TP53 germline mutations in adult patients with adrenocortical carcinoma","volume":"97","author":"Herrmann","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ejca.2018.02.028_bib15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","article-title":"Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations","volume":"27","author":"Gonzalez","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.02.028_bib16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1086\/302575","article-title":"Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors","volume":"65","author":"Varley","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"22","key":"10.1016\/j.ejca.2018.02.028_bib17","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/jnci\/86.22.1707","article-title":"High frequency of germline p53 mutations in childhood adrenocortical cancer","volume":"86","author":"Wagner","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2018.02.028_bib18","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1210\/jc.2012-2198","article-title":"Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma","volume":"98","author":"Raymond","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejca.2018.02.028_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/1897-4287-10-18","article-title":"Familial gastric cancer: detection of a hereditary cause helps to understand its etiology","volume":"10","author":"Vogelaar","year":"2012","journal-title":"Hered Cancer Clin Pract"},{"issue":"4","key":"10.1016\/j.ejca.2018.02.028_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2217\/14796694.4.4.553","article-title":"Hereditary diffuse gastric cancer: surgery, surveillance and unanswered questions","volume":"4","author":"Cisco","year":"2008","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2018.02.028_bib21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","article-title":"Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer","volume":"14","author":"George","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.02.028_bib22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10549-017-4198-4","article-title":"Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers","volume":"163","author":"Krammer","year":"2017","journal-title":"Breast Canc Res Treat"},{"issue":"7483","key":"10.1016\/j.ejca.2018.02.028_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature12981","article-title":"Realizing the promise of cancer predisposition genes","volume":"505","author":"Rahman","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2018.02.028_bib24","series-title":"Molecular testing strategies for Lynch syndrome in people with colorectal cancer","author":"NICE","year":"2017"},{"key":"10.1016\/j.ejca.2018.02.028_bib25","series-title":"TruSight cancer - methodology used for cancer predisposition gene tests","author":"TGLclinical","year":"2013"},{"key":"10.1016\/j.ejca.2018.02.028_bib26","unstructured":"TGLclinical services. available from www.tglclinical.com\/services."},{"key":"10.1016\/j.ejca.2018.02.028_bib27","series-title":"Mainstreaming cancer genetics","year":"2017"},{"key":"10.1016\/j.ejca.2018.02.028_bib28","doi-asserted-by":"crossref","first-page":"29506","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2018.02.028_bib29","first-page":"393","article-title":"Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer","volume":"9","author":"McVeigh","year":"2017","journal-title":"Breast Cancer Dove Med Press"},{"issue":"4","key":"10.1016\/j.ejca.2018.02.028_bib30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3322\/canjclin.57.4.242","article-title":"Young adult oncology: the patients and their survival challenges","volume":"57","author":"Bleyer","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ejca.2018.02.028_bib31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archpediatrics.2010.4","article-title":"Differences in non-Hodgkin lymphoma survival between young adults and children","volume":"164","author":"Tai","year":"2010","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"10.1016\/j.ejca.2018.02.028_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/pch\/11.2.103","article-title":"Adolescents and young adults with cancer: an orphaned population","volume":"11","author":"Fernandez","year":"2006","journal-title":"Paediatr Child Health"},{"issue":"1","key":"10.1016\/j.ejca.2018.02.028_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.17980\/2017.29","article-title":"Personalisation of Therapy \u2013 clinical impact and relevance of genetic mutations in tumours","volume":"3","author":"McVeigh","year":"2017","journal-title":"Cancer Res Front"},{"key":"10.1016\/j.ejca.2018.02.028_bib34","first-page":"1","article-title":"Clinical implications of germline mutations in breast cancer: TP53","author":"Schon","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 6","key":"10.1016\/j.ejca.2018.02.028_bib35","doi-asserted-by":"crossref","first-page":"vi64","DOI":"10.1093\/annonc\/mdt354","article-title":"Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Labianca","year":"2013","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2018.02.028_bib36","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ijc.29128","article-title":"Tumor genome analysis includes germline genome: are we ready for surprises?","volume":"136","author":"Catenacci","year":"2015","journal-title":"Int J Cancer"},{"issue":"283","key":"10.1016\/j.ejca.2018.02.028_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa7161","article-title":"Personalized genomic analyses for cancer mutation discovery and interpretation","volume":"7","author":"Jones","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.ejca.2018.02.028_bib38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genetics in Medicine"},{"key":"10.1016\/j.ejca.2018.02.028_bib39","series-title":"Practice guidelines for the evaluation of pathogenicity and the reporting of sequence variants in clinical molecular genetics","author":"Wallis","year":"2013"},{"key":"10.1016\/j.ejca.2018.02.028_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ebiom.2016.04.005","article-title":"Comprehensive RNA analysis of the NF1 gene in classically affected NF1 affected individuals meeting NIH criteria has high sensitivity and mutation negative testing is reassuring in isolated cases with pigmentary features only","volume":"7","author":"Evans","year":"2016","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.ejca.2018.02.028_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"Ferner","year":"2007","journal-title":"J Med Genet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918302363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918302363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T13:53:53Z","timestamp":1657029233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918302363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":41,"alternative-id":["S0959804918302363"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.02.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}